Pharmaceutical services: focus on fluorqinolones
https://doi.org/10.34680/2076-8052.2021.3(124).65-72
Abstract
Fluoroquinolones are the most commonly used drugs in everyday clinical practice. The prevalence and frequency of fluoroquinolones administration are justified by its therapeutic effects. The antimicrobial spectrum, mechanism of action, and pharmacokinetic features distinguish these medicines from drugs of other pharmacological groups. The 2019 sales data and a range of fluoroquinolones in a pharmacy chain of Veliky Novgorod and Pskov are studied. It has been established that Ciprofloxacin medicines (International nonproprietary names), produced in India and Russia, dominate in the pharmaceutical market. The comparative analysis of the results of an anonymous survey of 169 pharmaceutical specialists in Veliky Novgorod and 98 specialists in Pskov was held. The important significance of post-marketing surveillance of licensed medicines, namely, fluoroquinolones, is shown in this article. Pharmacists have more and more adverse drug reactions to medicines in the practice. The problem is that pharmacists rarely inform patients about adverse drug reactions and provide pharmaceutical services about antibacterial medicines to patients. The risk points of pharmaceutical counselling were identified, and was proved that pharmacists need educational programs on pharmacovigilance.
About the Authors
G. A. Antropova
Новгородский государственный университет имени Ярослава Мудрого
Russian Federation
Russian Federation
T. I. Okonenko
Новгородский государственный университет имени Ярослава Мудрого
Russian Federation
Russian Federation
References
1. Sood D., Kumar N., Singh A., Sakharkar M.K., Tomar V., Chandra R. Antibacterial and pharmacological evaluation of fluoroquinolones: a chemoinformatics approach. Genomics Inform, 2018, vol. 16(3), p. 44.
2. Prakticheskoe rukovodstvo po antiinfektsionnoy terapii: rukovodstvo dlya vrachey [A practical guide to antiinfectious therapy: a guide for doctors] / ed. by. L.S.Strachunsky, Yu.B.Belousov, S.N.Kozlov. Smolensk, MAKMAX Publ., 2007, 464 p.
3. Dovgan' E.V. Obzor topicheskikh form antimikrobnykh preparatov, primenyaemykh v oftal'mologii [Topical antimicrobial agents in ophthalmology. A review]. Oftal'mologiia – Ophthalmology, 2014, vol.11, no.2, p.10-18.
4. Yakovlev V.P. Antimikrobnye preparaty gruppy ftorkhinolonov [Antimicrobial drugs of the fluoroquinolone group]. Consilium medicum, 2006, no.1, pp.35-41.
5. Profilaktika neblagopriyatnykh pobochnykh reaktsiy [Prevention of adverse side effects]. Ed. by N.V.Yurgel. Moscow, GEOTAR-Media Publ., 2009, 450 p.
6. Damanhouri Z.A., Alkreathy H.M., Ali A.S. et al. The potential role of Fluoroquinolones in the management of Covid-19 a rapid review. J Adv Pharm Edu Res 2021, v.11(1), p.128-134.
7. Kozlov R.S., Golub A.V., Dekhnich A.V., Sukhorukova M.V Antibiotikorezistentnost' gramotritsatel'nykh vozbuditeley oslozhnennykh intraabdominal'nykh infektsiy v Rossii [Antimicrobial resistance of gram-negative microorganisms causing complicated intra-abdominal infections in Russia. Clinical microbiology and antimicrobial chemotherapy, 2015, vol.17, no.3, pp.228-237.
8. Fursova N.K. Sovremennoe sostoyanie antibiotikorezistentnosti vozbuditeley gospital'nykh infektsiy. [The current state of antibiotic resistance of pathogens of nosocomial infections]. In: Proc. of “Bioeticheskie problemy razvitiya geneticheskikh tekhnologiy v Rossiyskoy Federatsii” [Bioethical problems of the development of genetic technologies in the Russian Federation]. Moscow, 2020, p.49-51.
9. Strachunskiy L.S., Krechikov V.A. Moksifloksatsin – ftorkhinolon novogo pokoleniya s shirokim spektrom aktivnosti (obzor literatury) [Moxifloxacin is a new generation fluoroquinolone with a wide spectrum of activity (literature review)] // Klinicheskaya mikrobiologiya i antimikrobnaya ximioterapiya [Clinical microbiology and antimicrobial chemotherapy], 2001, vol.3, no.3, pp.243–260.
10. Dalhoff A. Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdisciplinary Perspectives on Infectious Diseases, 2012, 37 p. ID 976273 DOI:10.1155/2012/976273
11. Noman A.T., Qazi A.H., Alqasrawi M. et al. Fluoroquinolones and the risk of aortopathy: A systematic review and metaanalysis. Int J Cardiol, 2019; v.274, p.299-302.
12. Briasoulis A., Agarwal V., Pierce W.J. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology, 2011, vol.120(2), pp.103-10.
13. WHO. Patient Safety and Risk Management Service Delivery and Safety. September, 2019. Available at: https://www.who.int/features/factfiles/patient_safety/patientsafety-fact-file.pdf?ua=1 (accessed 02.03.2021).
14. Yashina N.V., Antropova G.A., Okonenko T.I. Farmatsevticheskoe konsul'tirovanie i nezhelatel'nye reaktsii na lekarstvennye preparaty [Pharmaceutical consulting and adverse drug reactions]. Proc. Of 10th conference of postgraduates and students “Molodaya farmaciya – potencial budushhego” [Young pharmacy is the potential of the future]», Sanct Peterburg, 2020, SPXFU Publ., pp.463-466.
15. Rossiya v tsifrakh. 2020: Kratkiy statisticheskiy sbornik [Russia in numbers. The 2020 Brief statistical collection]. Moscow, 2020, Rosstat Publ., 550 p.
Review
For citations:
Antropova G.A., Okonenko T.I. Pharmaceutical services: focus on fluorqinolones. Title in english. 2021;(3(124)):65-72. (In Russ.) https://doi.org/10.34680/2076-8052.2021.3(124).65-72
Views:
63
Email this article 